View Clinical Trial (Medical Research Study)
Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia - NCT00588731-06511(Clinical Trial 197330)
ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.
| City: |
|
New Haven |
|
State:
|
|
CT |
| Zip Code: |
|
06511 |
| Conditions: |
|
Schizophrenia - Schizoaffective Disorder |
| Purpose: |
|
This study is a six-week, randomized, placebo-controlled, fixed dose trial comparing
cannabidiol Vs. placebo added to a stable dose of antipsychotic medications in patients
diagnosed with schizophrenia.
|
| Study summary: |
|
|
| Criteria: |
|
Inclusion Criteria:
- Schizophrenia or Schizoaffective disorder (DSM-IV SCID-confirmed),
Exclusion Criteria:
- Women who are pregnant, nursing or unwilling to use appropriate birth control
measures during study participation. |
|
|
|
| Study is available at: |
|
Yale University
New Haven, CT 06511
United States
Primary Contact:
Ashley M Schnakenberg, B.S.
Email: ashley.schnakenberg@yale.edu
Phone: 203-932-5711 |
|
|
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
|
| Trials Alerts: |
|
If you would like to be
notified of new clinical trials as they become available please
register for a free account.
|
|
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
March 22, 2011 |
Modifications to
this listing: |
|
Only selected fields are shown, please use the link
above to view all information about this clinical trial. |
|
|
|
|
|
|
|
|